Hypoxia, a hallmark of most solid tumours, is a negative prognostic factor due to its association
with an aggressive tumour phenotype and therapeutic resistance. Given its prominent …

Over the past 15 years, there has been great interest in the potential to repurpose the
diabetes drug, metformin, as a cancer treatment. However, despite considerable efforts being …

Apart from high-risk scenarios such as the presence of highly penetrant genetic mutations,
breast screening typically comprises mammography or tomosynthesis strategies defined by …

An in vivo model of antiangiogenic therapy allowed us to identify genes upregulated by
bevacizumab treatment, including Fatty Acid Binding Protein 3 (FABP3) and FABP7, both of …

Background Trastuzumab duocarmazine is a novel HER2-targeting antibody–drug conjugate
comprised of trastuzumab covalently bound to a linker drug containing duocarmycin. …

… Dr Lord reported funding of clinical trial activities from the National Institute for Health …
outside the submitted work; in addition, Dr Lord had a patent for Mitox Therapeutics issued related …

Late-phase clinical trials investigating metformin as a cancer therapy are underway. However,
there remains controversy as to the mode of action of metformin in tumors at clinical doses…

Tumor hypoxia is associated with poor patient outcomes in estrogen receptor-α–positive (ERα
+ ) breast cancer. Hypoxia is known to affect tumor growth by reprogramming metabolism …

Oxidative phosphorylation (OXPHOS) takes place in mitochondria and is the process whereby
cells use carbon fuels and oxygen to generate ATP. Formerly OXPHOS was thought to be …

Hypoxia is a feature of most solid tumors and is associated with poor prognosis in several
cancer types, including breast cancer. The master regulator of the hypoxic response is the …